Biohaven Ltd. (NYSE:BHVN) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its holdings in Biohaven Ltd. (NYSE:BHVN - Free Report) by 45.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,001 shares of the company's stock after selling 7,529 shares during the period. SG Americas Securities LLC's holdings in Biohaven were worth $336,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BHVN. Point72 Asset Management L.P. raised its position in shares of Biohaven by 745.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company's stock valued at $74,969,000 after buying an additional 1,322,922 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Biohaven by 563.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company's stock valued at $25,416,000 after buying an additional 431,954 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Biohaven by 85.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company's stock valued at $40,448,000 after acquiring an additional 372,737 shares in the last quarter. Janus Henderson Group PLC raised its stake in Biohaven by 5.6% during the 3rd quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company's stock valued at $311,142,000 after buying an additional 328,099 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Biohaven by 600.9% during the third quarter. Wellington Management Group LLP now owns 243,167 shares of the company's stock valued at $12,151,000 after purchasing an additional 208,472 shares in the last quarter. 88.78% of the stock is owned by institutional investors.

Insider Transactions at Biohaven

In other Biohaven news, Director John W. Childs acquired 29,000 shares of the company's stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the purchase, the director now directly owns 2,368,741 shares in the company, valued at $85,132,551.54. The trade was a 1.24 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 16.00% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BHVN shares. HC Wainwright reiterated a "buy" rating and set a $59.00 price objective on shares of Biohaven in a research note on Tuesday, December 17th. Royal Bank of Canada reissued an "outperform" rating and set a $61.00 price objective (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. TD Cowen lifted their target price on shares of Biohaven from $55.00 to $75.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Biohaven in a research report on Tuesday, December 17th. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Biohaven has a consensus rating of "Buy" and an average target price of $63.00.

Biohaven Stock Down 1.2 %

Shares of Biohaven stock traded down $0.48 during trading on Friday, reaching $38.40. The company's stock had a trading volume of 546,102 shares, compared to its average volume of 842,000. The firm has a market cap of $3.88 billion, a PE ratio of -4.11 and a beta of 1.28. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The business's 50-day moving average price is $38.90 and its 200-day moving average price is $42.61.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.03). Equities analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.